Tag Archives: vrx

Valeant Ends Prince Charming Act; Allergan Hopes Rise

Valeant Pharmaceuticals (VRX) shares popped on upbeat guidance and as the addition of Actavis (ACT) to the Allergan-Valeant-Salix triangle lifted Valeant’s chances for an Allergan takeover. Valeant said it expects to beat third-quarter analyst views on revenue and its own cash EPS guidance when it reports on Oct. 20. It also sees same-store organic growth exceeding 15% in Q3, with its Bausch + Lomb segment delivering more than 10% organic growth.

Video: Valeant, Allergan Settle Suit, Allow Shareholder Vote

Specialty-drug giant Valeant Pharmaceuticals International (VRX) agreed to drop its litigation against hostile-takeover target Allergan in exchange for Allergan allowing the originally scheduled Dec. 18 special shareholder meeting that could speed the potential merger. But while the meeting go-ahead makes a merger likelier, BMO Capital Markets analyst David Maris reported after a visit with Allergan (AGN) executives that they still sounded

Valeant, Allergan Settle Suit, Allow Shareholder Vote

Specialty-drug giant Valeant Pharmaceuticals International (VRX) agreed to drop its litigation against hostile-takeover target Allergan in exchange for Allergan allowing the originally scheduled Dec. 18 special shareholder meeting that could speed the potential merger. But while the meeting go-ahead makes a merger likelier, BMO Capital Markets analyst David Maris reported after a visit with Allergan (AGN) executives that they still sounded